GlassScriptPhysician profile
Damir Kusmic
NPI 1780039727
$4,176.21
in general payments reported to CMS, 2019-2025
23 companies · $1,514 in 2025
The $1,514 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $76.29 · 2023: $613 · 2024: $1,973 · 2025: $1,514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,086 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,086.16 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,454.11 | 2023-2025 | |
| Janssen Biotech, INC. | $462.98 | 2023-2025 | Tremfya, Stelara, Remicade |
| Phathom Pharmaceuticals, INC. | $443.12 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $332.92 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Madrigal Pharmaceuticals | $206.05 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $172.20 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $152.75 | 2023-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $137.48 | 2023-2025 | Dupixent |
| Pfizer INC. | $125.39 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $110.92 | 2023 | Stelara |
| Ironwood Pharmaceuticals, INC | $98.56 | 2023-2024 | Linzess |
| Gilead Sciences, INC. | $98.24 | 2020-2025 | |
| Qol Medical, LLC | $58.56 | 2023-2024 | Sucraid, Sucraid |
| Lilly USA, LLC | $57.06 | 2024 | Omvoh |
| Aimmune Therapeutics, INC. | $46.14 | 2024-2025 | Zenpep |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $37.61 | 2024 | Rebyota |
| Intercept Pharmaceuticals, INC. | $34.45 | 2023-2025 | Ocaliva |
| Evoke Pharma, INC. | $34.18 | 2024 | |
| Celgene Corporation | $32.62 | 2024 | Zeposia |
| Merck Sharp & Dohme LLC | $24.59 | 2023 | Dificid |
| Boston Scientific Corporation | $20.93 | 2025 | Resolution 360 Clip |
| Nestle Healthcare Nutrition INC. | $18.68 | 2023 | |
| Ardelyx, INC. | $16.67 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damir Kusmic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.